More about
Her2-Low Disease
News
June 02, 2024
3 min read
Save
Trastuzumab deruxtecan improves PFS in pretreated breast cancer
CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.